Aminobisphosphonates and Toll-Like Receptor Ligands: Recruiting V&ggr;9Vδ2 T Cells for the Treatment of Hematologic Malignancy

Publisher： Bentham Science Publishers

E-ISSN： 1875-533x|18|34|5206-5216

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.18, Iss.34, 2011-12, pp. : 5206-5216

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Evaluation of Lipopeptides as Toll-like Receptor 2 Ligands

By  

Current Drug Delivery, Vol. 14, Iss. 7, 2017-10 ,pp. : 935-943

Bentham Science Publishers

Access to resources Recommend Favorite

Toll-like receptor 9 agonists as cancer therapeutics

By Holtick Udo   Scheulen Max E   von Bergwelt-Baildon Michael S   Weihrauch Martin R  

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 3, 2011-03 ,pp. : 361-372

Informa Healthcare

Access to resources Recommend Favorite

Early development of the Toll-like receptor 9 agonist, PF-3512676, for the treatment of patients with advanced cancers

By Tarhini Ahmad A   Kirkwood John M   Krieg Arthur M  

Expert Opinion on Drug Discovery, Vol. 4, Iss. 5, 2009-05 ,pp. : 587-603

Informa Healthcare

Access to resources Recommend Favorite

Albumin Induces Neuroprotection Against Ischemic Stroke by Altering Toll-Like Receptor 4 and Regulatory T Cells in Mice

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 12, Iss. 2, 2013-04 ,pp. : 220-227

Bentham Science Publishers

Access to resources Recommend Favorite

Specific loss of Toll-like receptor 2 on bone marrow derived cells decreases atherosclerosis in LDL receptor null mice

By Hasu Mirela   Thabet Mohamed   Tam Nancy   Whitman Stewart C.  

Canadian Journal of Physiology and Pharmacology, Vol. 89, Iss. 10, 2011-10 ,pp. : 737-742

NRC Research Press

Access to resources Recommend Favorite